Production of axial skeletal malformations with the nitric oxide synthesis inhibitor NG-nitro-L-arginine methyl ester (L-NAME) in the mouse
✍ Scribed by Gian Mario Tiboni; Francesca Marotta; Lisa Barbacane
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- English
- Weight
- 218 KB
- Volume
- 80
- Category
- Article
- ISSN
- 1542-9733
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
BACKGROUND: To test whether the differentiating embryo is susceptible to the teratogenic effects of the nitric oxide (NO) synthesis inhibitor N^G^‐nitro‐L‐arginine methyl ester (L‐NAME). METHODS: ICR‐(CD‐1) mice received a single intraperitoneal injection of L‐NAME at 90, 150, or 300 mg/kg on Gestation Day (GD) 8 or 9. Controls were treated with vehicle on GD 8 and 9. Teratological assessments were carried out near term (GD 18). RESULTS: Maternal treatment with a single dose of L‐NAME at 150 or 300 mg/kg on either GD 8 or 9 produced axial skeletal defects in the ICR (CD‐1) mouse fetuses. Other treatment‐related effects included increased embryo lethality and fetal growth restriction. CONCLUSIONS: This study provides evidence that in utero exposure to L‐NAME can affect organogenesis of the axial skeleton. Birth Defects Res (Part B) 80:28–33, 2007. © 2007 Wiley‐Liss, Inc.